CRISPR can be used to treat genetic diseases, fight cancer, grow hardier crops, diagnose infections in minutes, and potentially eliminate malaria-carrying mosquitoes. It is the most versatile gene-editing tool ever developed, and its applications span medicine, agriculture, diagnostics, and environmental engineering. As of 2024, one CRISPR therapy has received full FDA approval, over 80 clinical trials are underway across multiple diseases, and dozens of agricultural projects are altering the food supply.
Treating Genetic Blood Disorders
The first and so far only FDA-approved CRISPR therapy is Casgevy, made by Vertex Pharmaceuticals, for sickle cell disease in patients aged 12 and older. Sickle cell disease causes red blood cells to deform into rigid, crescent shapes that block blood vessels, triggering episodes of extreme pain called vaso-occlusive crises. Casgevy works by editing a patient’s own blood stem cells to reactivate fetal hemoglobin, a form of hemoglobin that humans naturally produce before birth but then switch off. With fetal hemoglobin levels raised, red blood cells stay flexible and functional.
In clinical trials, patients who received Casgevy saw a significant drop in pain crises and no longer needed regular blood transfusions. The treatment targets a specific gene that normally suppresses fetal hemoglobin production. By disabling that gene in blood stem cells, the therapy essentially flips a molecular switch that the body already has, rather than inserting something foreign. This approval in December 2023 marked the first time a CRISPR-based treatment cleared regulatory review anywhere in the world.
Engineering Immune Cells to Fight Cancer
Cancer represents the single largest category of CRISPR clinical trials, accounting for about 42% of all registered studies. The most active area involves enhancing a treatment called CAR-T cell therapy, where a patient’s immune cells are removed, genetically reprogrammed to recognize cancer, and infused back into the body. CRISPR makes these modified immune cells more effective by disabling the molecular “brakes” that tumors exploit to shut down immune responses.
Blood cancers are the primary targets right now, including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma, with research expanding into acute myeloid leukemia and T-cell cancers. One particularly clever application addresses a problem called fratricide: when immune cells engineered to attack T-cell cancers accidentally destroy each other because they share the same surface markers as the cancer. CRISPR can strip those markers from the therapeutic cells so they attack only the tumor.
CRISPR also enables the creation of “universal” CAR-T cells, donor cells edited so the recipient’s body won’t reject them. Current CAR-T therapy requires using each patient’s own cells, which is expensive and time-consuming. Universal cells could be manufactured in bulk and stored, making the treatment faster and far cheaper to deliver.
Diagnosing Infections in Under an Hour
Two CRISPR-based diagnostic platforms, called SHERLOCK and DETECTR, can identify viruses and bacteria in a fraction of the time traditional lab tests require. Both work on the same principle: a CRISPR protein is programmed to recognize a specific genetic sequence from a pathogen. When it finds a match, the protein activates and begins cutting nearby molecules indiscriminately. Researchers attach fluorescent tags to those nearby molecules, so when cutting occurs, the tags light up, confirming the pathogen is present.
DETECTR, which uses the Cas12a protein, can deliver results in roughly 30 minutes, with the full analysis taking about an hour. SHERLOCK, built around a different protein called Cas13, can detect a target in as little as five minutes once the initial sample preparation is complete. Both systems work as simple lateral flow assays, similar in format to a home pregnancy test, meaning they don’t require expensive laboratory equipment. This makes them especially promising for rapid screening during outbreaks or in remote settings with limited infrastructure.
Making Crops Tougher and More Nutritious
CRISPR is being used across a wide range of staple crops to improve yields, nutritional content, and resilience to drought. In maize, editing a gene called ARGOS8 reduced the plant’s sensitivity to a stress hormone, resulting in substantially higher grain production during dry seasons compared to unmodified varieties. Similar drought-tolerance work has been done in rice, wheat, tomato, cassava, cotton, sugarcane, and papaya, each targeting different pathways the plant uses to cope with water stress.
Beyond drought resistance, CRISPR has produced high-amylose wheat with significantly more resistant starch and protein, both beneficial for human health. In the oilseed crop camelina, editing a single gene slashed unhealthy very-long-chain fatty acids from about 22% of total fat content to less than 2%, while boosting healthier unsaturated fats. Tomatoes have been a particularly active target: researchers have used CRISPR to produce larger fruits, slow softening to extend shelf life, and create yellow, pink, and purple varieties by tweaking pigment genes.
Unlike older genetic modification techniques that insert DNA from other organisms, many CRISPR edits simply disable or tweak genes the plant already has. This distinction matters for regulation. Several countries have streamlined approval processes for gene-edited crops that don’t contain foreign DNA, which has accelerated the path from lab to field.
Eliminating Disease-Carrying Mosquitoes
One of the most ambitious applications of CRISPR is the gene drive: a genetic system designed to spread a chosen trait through an entire wild population within just a few generations. For malaria control, researchers are developing CRISPR-based gene drives in Anopheles mosquitoes that would either crash mosquito populations or make them unable to carry the malaria parasite.
A standard gene is inherited by about 50% of offspring. A gene drive cheats this system. It encodes the CRISPR cutting machinery at a specific location in the mosquito’s DNA. When a mosquito carrying the drive mates with a wild mosquito, the drive cuts the corresponding spot on the partner chromosome and copies itself into the break. The result is that nearly all offspring inherit the drive, not just half, allowing it to sweep through a population far faster than any natural gene could.
The most advanced version targets a gene called doublesex, which is essential for female mosquito development. In large cage trials, this drive spread to fixation and collapsed the captive population. However, no gene drive mosquitoes have been released into the wild yet. Regulatory approval is still in progress, and scientists continue to debate how to manage the ecological consequences of suppressing or transforming an entire species. Replacement drives, which make mosquitoes resistant to malaria rather than killing them off, are also in development but currently face challenges with resistance evolution and effector potency.
Precision Editing With Newer Tools
Standard CRISPR/Cas9 works by cutting both strands of DNA at a target site, then relying on the cell’s own repair machinery to fix the break. That repair process is imprecise. It often introduces small random insertions or deletions, which is fine when the goal is to disable a gene entirely but not ideal when you need a specific, exact change.
Newer techniques solve this problem. Prime editing, sometimes called a “search and replace” tool for DNA, can write specific sequences into the genome without making a full double-strand break. In rice and wheat, prime editing has achieved precise insertions of up to 15 DNA letters and deletions of up to 40 letters, along with targeted multi-base swaps. Base editors offer another option, chemically converting one DNA letter directly into another at a specific site. These precision tools are expanding what CRISPR can do from simply knocking out genes to rewriting them letter by letter.
The Regulatory Line: Somatic vs. Heritable Editing
All approved and currently trialed CRISPR therapies are somatic, meaning they edit cells in a way that affects only the treated individual. The changes are not passed to future generations. Editing that alters eggs, sperm, or embryos, called heritable or germline editing, remains a different matter entirely.
The World Health Organization has stated explicitly that it would be irresponsible for anyone to proceed with clinical applications of heritable genome editing at this time. A WHO Expert Advisory Committee published a governance framework in 2021 calling for oversight at both national and international levels. The core concern is straightforward: somatic edits can be evaluated in a single patient, but germline changes ripple through descendants indefinitely, with consequences that cannot be fully predicted or consented to by those future individuals.
As of early 2025, no country has approved heritable human genome editing for clinical use. The over 80 CRISPR clinical trials currently registered worldwide all operate within the somatic boundary, treating diseases in living patients without altering the human germline.